Cybin Inc. (NEO:CYBN)
Canada · Delayed Price · Currency is CAD | Market Cap | 464.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -120.90M |
| Shares Out | n/a |
| EPS (ttm) | -5.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,755 |
| Average Volume | 15,893 |
| Open | 9.62 |
| Previous Close | 9.10 |
| Day's Range | 9.02 - 9.64 |
| 52-Week Range | 6.95 - 15.55 |
| Beta | 1.09 |
| RSI | 62.04 |
| Earnings Date | Feb 12, 2026 |
About Cybin
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for M... [Read more]
News
Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Helus Pharma (HELP)
Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Helus Pharma (HELP)
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative n...
Cybin (CYBN) to Transfer Listing to Nasdaq in 2026
Cybin (CYBN) to Transfer Listing to Nasdaq in 2026
Cybin (CYBN) Set to Switch U.S. Listing from NYSE to Nasdaq
Cybin (CYBN) Set to Switch U.S. Listing from NYSE to Nasdaq
Cybin to move U.S. stock listing to Nasdaq from NYSE American
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative ...
Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News
Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges
Q2 2026 Cybin Inc Earnings Call Transcript
Q2 2026 Cybin Inc Earnings Call Transcript
Cybin (CYBN) Analyst Rating Update: Canaccord Genuity Lowers PT to $45 | CYBN Stock News
Cybin (CYBN) Analyst Rating Update: Canaccord Genuity Lowers PT to $45 | CYBN Stock News
Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript
Cybin Inc. (CYBN) Q2 2026 Earnings Call November 13, 2025 8:00 AM ESTCompany ParticipantsEric So - Co-Founder, Interim CEO, President & Executive...
Cybin (CYBN) Bolsters Financial Position to Advance Clinical Trials
Cybin (CYBN) Bolsters Financial Position to Advance Clinical Trials
Cybin (CYBN) Reports Narrowed Q2 Net Loss
Cybin (CYBN) Reports Narrowed Q2 Net Loss
Cybin reports Q2 results
Cybin (CYBN) reports Q2 net loss drop to $33.7M vs. $41.9M last year.
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE: EPC) is projected to report quarterly earnings at $0.81 per share on revenue of $534.10 million. • National Energy Services (NASDAQ...
Cybin Q2 2026 Earnings Preview
What's Next: Cybin's Earnings Preview
Cybin (AMEX: CYBN) is gearing up to announce its quarterly earnings on Thursday, 2025-11-13. Here's a quick overview of what investors should know before the release. Analysts are estimating that Cyb...
Cybin to Participate in the Jefferies Global Healthcare Conference in London
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin Announces Closing of $175 Million Registered Direct Offering
TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental...
Cybin Announces $175 Million Registered Direct Offering
TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Danie...